Comprehensive Analysis of CPA4 as a Poor Prognostic Biomarker Correlated with Immune Cells Infiltration in Bladder Cancer

被引:7
作者
Wei, Chengcheng [1 ]
Zhou, Yuancheng [1 ]
Xiong, Qi [2 ]
Xiong, Ming [1 ]
Hou, Yaxin [1 ]
Yang, Xiong [1 ]
Chen, Zhaohui [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Urol, Union Hosp, Wuhan 430074, Peoples R China
[2] Chongqing Med Univ, Chongqing Key Lab Mol Oncol & Epigenet, Chongqing 400000, Peoples R China
来源
BIOLOGY-BASEL | 2021年 / 10卷 / 11期
关键词
CPA4; bladder urothelial carcinoma; immune cells; T cell exhaustion; checkpoint; HUMAN CARBOXYPEPTIDASE A4; EXPRESSION; SURVIVAL; ASSOCIATION; REGULATOR; CARCINOMA;
D O I
10.3390/biology10111143
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Simple Summary: The overexpression of Carboxypeptidase A4 (CPA4) has been observed in plenty of types of cancer and has been elucidated to promote tumor growth and invasion; however, its role in bladder urothelial carcinoma (BLCA) is still unclear. Therefore, we aimed to show the prognostic role of CPA4 and its relationship with immune infiltrates in BLCA. We confirmed that the overexpression of CPA4 is associated with shorter overall survival, disease-specific survival, progress-free intervals, and higher dead events. Moreover, we found that several infiltrating immune cells (Th1cell, Th2 cell, T cell exhaustion, and Tumor-associated macrophage) were correlated with the expression of CPA4 in bladder cancer using TIMER2 and GEPIA2. In conclusion, CPA4 may be a novel and great prognostic biomarker based on bioinformation analysis in BLCA.Carboxypeptidase A4 (CPA4) has shown the potential to be a biomarker in the early diagnosis of certain cancers. However, no previous research has linked CPA4 to therapeutic or prognostic significance in bladder cancer. Using data from The Cancer Genome Atlas (TCGA) database, we set out to determine the full extent of the link between CPA4 and BLCA. We further analyzed the interacting proteins of CPA4 and infiltrated immune cells via the TIMER2, STRING, and GEPIA2 databases. The expression of CPA4 in tumor and normal tissues was compared using the TCGA + GETx database. The connection between CPA4 expression and clinicopathologic characteristics and overall survival (OS) was investigated using multivariate methods and Kaplan-Meier survival curves. The potential functions and pathways were investigated via gene set enrichment analysis. Furthermore, we analyze the associations between CPA4 expression and infiltrated immune cells with their respective gene marker sets using the ssGSEA, TIMER2, and GEPIA2 databases. Compared with matching normal tissues, human CPA4 was found to be substantially expressed. We confirmed that the overexpression of CPA4 is linked with shorter OS, DSF(Disease-specific survival), PFI(Progression-free interval), and increased diagnostic potential using Kaplan-Meier and ROC analysis. The expression of CPA4 is related to T-bet, IL12RB2, CTLA4, and LAG3, among which T-bet and IL12RB2 are Th1 marker genes while CTLA4 and LAG3 are related to T cell exhaustion, which may be used to guide the application of checkpoint blockade and the adoption of T cell transfer therapy.
引用
收藏
页数:18
相关论文
共 49 条
  • [1] Incidence, survival and mortality rates of stage-specific bladder cancer in United States: A trend analysis
    Abdollah, Firas
    Gandaglia, Giorgio
    Thuret, Rodolphe
    Schmitges, Jan
    Tian, Zhe
    Jeldres, Claudio
    Passoni, Niccolo Maria
    Briganti, Alberto
    Shariat, Shahrokh F.
    Perrotte, Paul
    Montorsi, Francesco
    Karakiewicz, Pierre I.
    Sun, Maxine
    [J]. CANCER EPIDEMIOLOGY, 2013, 37 (03) : 219 - 225
  • [2] Development and External Validation of a Novel 12-Gene Signature for Prediction of Overall Survival in Muscle-Invasive Bladder Cancer
    Abudurexiti, MierXiati
    Xie, Huyang
    Jia, Zhongwei
    Zhu, Yiping
    Zhu, Yao
    Shi, Guohai
    Zhang, Hailiang
    Dai, Bo
    Wan, Fangning
    Shen, Yijun
    Ye, Dingwei
    [J]. FRONTIERS IN ONCOLOGY, 2019, 9
  • [3] European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-2019 Update
    Babjuk, Marko
    Burger, Maximilian
    Comperat, Eva M.
    Gontero, Paolo
    Mostafid, A. Hugh
    Palou, Joan
    van Rhijn, Bas W. G.
    Roupret, Morgan
    Shariat, Shahrokh F.
    Sylvester, Richard
    Zigeuner, Richard
    Capoun, Otakar
    Cohen, Daniel
    Dominguez Escrig, Jose Luis
    Hernandez, Virginia
    Peyronnet, Benoit
    Seisen, Thomas
    Soukup, Viktor
    [J]. EUROPEAN UROLOGY, 2019, 76 (05) : 639 - 657
  • [4] UNLOCKING BLADDER CANCER
    Berdik, Chris
    [J]. NATURE, 2017, 551 (7679) : S34 - S35
  • [5] Bladder Cancer Survivorship
    Bhanvadia, Sumeet K.
    [J]. CURRENT UROLOGY REPORTS, 2018, 19 (12)
  • [6] SnapShot: TCGA-Analyzed Tumors
    Blum, Amy
    Wang, Peggy
    Zenklusen, Jean C.
    [J]. CELL, 2018, 173 (02) : 530 - 530
  • [7] UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
    Chandrashekar, Darshan S.
    Bashel, Bhuwan
    Balasubramanya, Sai Akshaya Hodigere
    Creighton, Chad J.
    Ponce-Rodriguez, Israel
    Chakravarthi, Balabhadrapatruni V. S. K.
    Varambally, Sooryanarayana
    [J]. NEOPLASIA, 2017, 19 (08): : 649 - 658
  • [8] Improving gene set analysis of microarray data by SAM-GS
    Dinu, Irina
    Potter, John D.
    Mueller, Thomas
    Liu, Qi
    Adewale, Adeniyi J.
    Jhangri, Gian S.
    Einecke, Gunilla
    Famulski, Konrad S.
    Halloran, Philip
    Yasui, Yutaka
    [J]. BMC BIOINFORMATICS, 2007, 8 (1)
  • [9] Downregulation of CPA4 inhibits non small-cell lung cancer growth by suppressing the AKT/c-MYC pathway
    Fu, Yangyang
    Su, Lihuang
    Cai, Mengsi
    Yao, Boyang
    Xiao, Sisi
    He, Qinlian
    Xu, Le
    Yang, Lehe
    Zhao, Chengguang
    Wan, Tingting
    Shao, Lianyou
    Wang, Liangxing
    Huang, Xiaoying
    [J]. MOLECULAR CARCINOGENESIS, 2019, 58 (11) : 2026 - 2039
  • [10] BLADDER CANCER
    Grayson, Michelle
    [J]. NATURE, 2017, 551 (7679) : S33 - S33